KRT18 and metabolic dysfunction-associated steatohepatitis: Since liver enzymes and imaging are not able to predict the onset and presence of NASH [34], novel serum markers have been taken into account, such as the intermediate filament protein cytokeratin 18 (CK18), a fragment obtained after caspase-3-mediated cleavage of different substrates during the apoptotic process, one of the main mechanisms induced during NASH progression.